The European Lung Cancer Congress (ELCC) 2018, in Geneva, Switzerland, presented an array of exciting lung cancer trial updates. Speaking from the meeting, Marina Garassino, MD, of the Istituto Nazionale dei Tumori, Milan, Italy, discusses the Phase III ECHO-306/KEYNOTE-715 study (NCT03322566). This promising trial comprises three arms and is investigating pembrolizumab and epacadostat in non-small cell lung cancer (NSCLC). Dr Garassino discusses the design, underlying rationale and primary endpoints of the study.
Pembrolizumab and epacadostat for NSCLC: ECHO-306/KEYNOTE-715
